NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

$16.12

+0.23 (+1.45%)

(As of 06/2/2023 ET)

Compare

Today's Range: $16.04
▼
$16.15
50-Day Range: $15.84
▼
$17.11
52-Week Range: $12.28
▼
$17.15

Volume: 1.29 million shs
Average Volume: 2.06 million shs
Market Capitalization: $51.01 billion

P/E Ratio: 20.94
Dividend Yield: 1.67%
Price Target: $24.67

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 53.0% Upside
$24.67 Price Target
Short Interest: Healthy
0.18% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.40
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

347th out of 983 stocks

Pharmaceutical Preparations Industry

160th out of 486 stocks

3.4

Analyst's Opinion

Consensus Rating
Takeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.67, Takeda Pharmaceutical has a forecasted upside of 53.0% from its current price of $16.12.
Amount of Analyst Coverage
Takeda Pharmaceutical has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.18% of the float of Takeda Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Takeda Pharmaceutical has recently decreased by 1.03%, indicating that investor sentiment is improving.

1.7

Dividend Strength

Dividend Yield
Takeda Pharmaceutical pays a meaningful dividend of 1.70%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Takeda Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Takeda Pharmaceutical is 35.07%. This payout ratio is at a healthy, sustainable level, below 75%.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TAK.

1.3

News and Social Media Coverage

News Sentiment
Takeda Pharmaceutical has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 6 articles on an average week.
Search Interest
Only 13 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.
Percentage Held by Institutions
Only 2.05% of the stock of Takeda Pharmaceutical is held by institutions.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Takeda Pharmaceutical is 20.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Takeda Pharmaceutical is 20.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.17.
Price to Earnings Growth Ratio
Takeda Pharmaceutical has a PEG Ratio of 8.93. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Takeda Pharmaceutical has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

June 2, 2023 | finance.yahoo.com

The area's largest life sciences employer, Takeda keeps reinventing itself

May 26, 2023 | bizjournals.com

This drug could help children with brain cancer. What's taken it so long?

June 4, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 26, 2023 | finance.yahoo.com

Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

May 25, 2023 | finance.yahoo.com

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

May 25, 2023 | fool.com

Takeda Pharmaceutical (NYSE: TAK)

May 25, 2023 | benzinga.com

Government of Japan Expresses its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment

May 22, 2023 | finance.yahoo.com

Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

June 4, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 17, 2023 | marketwatch.com

2023 Dipeptidyl Peptidase-4 Inhibitors Market Size and Insight Report in Pharma & Healthcare Sector | with [100 Pages] and Forecast till 2031

May 17, 2023 | marketwatch.com

Axial Spondyloarthritis Market Analysis by Size, Share, Trends, Emerging Trends, Qualitative Outlook and Worldwide Forecast to 2030

May 17, 2023 | americanbankingnews.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

May 17, 2023 | marketwatch.com

2023-2030 Blow-Fill-Seal (BFS) Technology Market: Highlights with Growth Rate

May 16, 2023 | benzinga.com

Global Blood Cancer Drugs Market Report 2023: Increasing Prevalence of Blood Cancer Cases Drives Growth

May 16, 2023 | finance.yahoo.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2022 Earnings Call Transcript

May 15, 2023 | benzinga.com

Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth

May 15, 2023 | americanbankingnews.com

Takeda Pharmaceutical (NYSE:TAK) Issues FY 2023 Earnings Guidance

May 11, 2023 | msn.com

Takeda FY22 sales grow but FY23 outlook weighed down by generic impact

May 11, 2023 | finance.yahoo.com

Takeda Moves Out From Licensing Agreement With Theravance Biopharma

May 11, 2023 | marketwatch.com

Takeda Pharmaceutical 4Q Rev Y960.00B, Given Y3.07T Rev in Preceding 9 Mos, WSJ Calculation Shows>4502.TO

May 11, 2023 | finance.yahoo.com

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

May 10, 2023 | finance.yahoo.com

Takeda Presents Real-World Clinical Effectiveness and Safety Results of Vedolizumab (ENTYVIO®) and Ustekinumab as First-Line Biologic Treatment for Crohn's Disease

May 8, 2023 | bizjournals.com

Takeda to lay off up to 186 employees in Massachusetts

May 5, 2023 | marketwatch.com

2030 Pericarditis Drugs Market Forecast: Positive Growth Trajectory Ahead

May 4, 2023 | marketwatch.com

Lipid Metabolism Disease Market Size and Forecast till 2031

May 3, 2023 | marketwatch.com

Narcolepsy Treatment Market Demand Overview, Growth Innovation, Latest Trends till 2029- Teva Pharmaceutical, Takeda, Jazz Pharmaceuticals

May 2, 2023 | marketwatch.com

Marine Pharmaceuticals Market SWOT Analysis, Sales, Revenue, Price and Gross Margin 2023-2030 Seattle Genetics, DSM, Eisai Co

See More Headlines

TAK Price History

30 days | 90 days | 365 days | Advanced Chart

TAK Company Calendar

Today: 6/04/2023
Next Earnings (Estimated): 7/27/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TAK
CUSIP: N/A
CIK: 1395064
Web: www.takeda.com
Phone: (166) 204-2111
Fax: 813-3278-2268
Employees: 47,347
Year Founded: 1781

Price Target and Rating

Average Stock Price Forecast: $24.67
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +53.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.77
Trailing P/E Ratio: 20.94
Forward P/E Ratio: 48.85
P/E Growth: 8.93
Net Income: $2.35 billion
Net Margins: 7.91%
Pretax Margin: 9.31%
Return on Equity: 12.73%
Return on Assets: 5.80%

Debt

Debt-to-Equity Ratio: 0.64
Current Ratio: 0.97
Quick Ratio: 0.57

Sales & Book Value

Annual Sales: $29.81 billion
Price / Sales: 1.71
Cash Flow: $3.64 per share
Price / Cash Flow: 4.43
Book Value: $14.86 per share
Price / Book: 1.08

Miscellaneous

Outstanding Shares: 3,164,620,000
Free Float: 3,163,350,000
Market Cap: $51.01 billion
Optionable: Optionable
Beta: 0.63

Social Links

Key Executives

Christophe Weber
President, CEO & Representative Director

Constantine Saroukos
Chief Financial Officer & Director

Andrew S. Plump
Director, President-Research & Development

Michael E. Mendelsohn
Chief Medical & Scientific Officer

Norimasa Takeda
Chief Accounting Officer & Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.
What is Takeda Pharmaceutical's stock price forecast for 2023?: 5 analysts have issued twelve-month price targets for Takeda Pharmaceutical's shares. Their TAK share price forecasts range from $20.00 to $30.00. On average, they anticipate the company's share price to reach $24.67 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.
How have TAK shares performed in 2023?: Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of 2023. Since then, TAK shares have increased by 3.3% and is now trading at $16.12.
View the best growth stocks for 2023 here.
When is Takeda Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our TAK earnings forecast.
What ETFs hold Takeda Pharmaceutical's stock?: ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), First Trust International IPO ETF (FPXI), Pacer Developed Markets International Cash Cows 100 ETF (ICOW), B.A.D. Etf (BAD), Pacer Global Cash Cows Dividend ETF (GCOW), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Zacks Multi-Asset Income ETF (CVY) and Pacer Trendpilot International ETF (PTIN).
Is Takeda Pharmaceutical a good dividend stock?: Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.70%. The dividend payout ratio is 35.07%. This payout ratio is at a healthy, sustainable level, below 75%.
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?: Takeda Pharmaceutical updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $3.28-$3.28 for the period. The company issued revenue guidance of $29.03 billion-$29.03 billion.
What other stocks do shareholders of Takeda Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?: Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
Who are Takeda Pharmaceutical's major shareholders?: Takeda Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.15%), Mondrian Investment Partners LTD (0.13%), Macquarie Group Ltd. (0.12%), Macquarie Group Ltd. (0.12%), Renaissance Technologies LLC (0.09%) and BlackRock Inc. (0.08%).
How do I buy shares of Takeda Pharmaceutical?: Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Takeda Pharmaceutical's stock price today?: One share of TAK stock can currently be purchased for approximately $16.12.
How much money does Takeda Pharmaceutical make?: Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $51.01 billion and generates $29.81 billion in revenue each year. The company earns $2.35 billion in net income (profit) each year or $0.77 on an earnings per share basis.
How many employees does Takeda Pharmaceutical have?: The company employs 47,347 workers across the globe.
Does Takeda Pharmaceutical have any subsidiaries?: The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?: Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

Takeda Pharmaceutical MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Takeda Pharmaceutical (NYSE:TAK) Stock

TAK Stock News Headlines

TAK Price History

TAK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

TAK Stock - Frequently Asked Questions

Overall MarketRank^™